Sakhuja V, Ramachandran R, Kohli H S, Jha V, Gupta K L, Rathi M, Joshi K, Nada R, Sharma A, Minz M
Department of Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Nephrol. 2013 Jul;23(4):287-91. doi: 10.4103/0971-4065.114504.
Post-transplant lymphoproliferative disorder (PTLD) is a well-recognized, but uncommon complication of organ transplantation. This study was a retrospective analysis of 2000 patients who underwent renal transplantation over a period of 30 years (1980-2010). Forty malignancies were diagnosed in 36 patients. Of these, 29 patients (1.45%) had PTLD (7 females, 22 males) accounting for 72.5% of all malignancies after transplantation. Twenty-two (75.8%) developed non-Hodgkin lymphoma and seven patients (24.2%) had myeloma. Diagnosis was made by biopsy of the involved organ in 21 patients (72.4%) and aspiration cytology in five patients (17.2%). In three patients, the diagnosis was made only at autopsy. Mean age at the time of diagnosis of PTLD was 41.9 years (range 21-69 years). Time interval from transplantation to the diagnosis of PTLD ranged from 3 months to 144 months with a median of 48 months. Only five patients (17.2%) developed PTLD within a year of transplantation. Twelve patients developed PTLD 1-5 years and 12 patients 5-10 years after transplantation. Organ involvement was extra nodal in 18 patients (82%). Thirteen (59%) patients had disseminated disease and nine (41%) had localized involvement of a single organ (brain-3, liver-1, allograft-1, perigraft node-1, retroperitoneal lymph nodes-3). Infiltration of the graft was noted in two patients. Patients with myeloma presented with backache, pathological fracture, unexplained anemia or graft dysfunction. PTLD was of B cell origin in 20 cases (70%). CD 20 staining was performed in 10 recent cases, of which 8 stained positive. Of the 26 patients diagnosed during life, 20 (69%) died within 1 year of diagnosis despite therapy. In conclusion, PTLD is encountered late after renal transplantation in the majority of our patients and is associated with a dismal outcome. The late onset in the majority of patients suggests that it is unlikely to be Epstein Barr virus related.
移植后淋巴细胞增生性疾病(PTLD)是器官移植中一种已被充分认识但并不常见的并发症。本研究对2000例在30年期间(1980 - 2010年)接受肾移植的患者进行了回顾性分析。36例患者被诊断出患有40种恶性肿瘤。其中,29例患者(1.45%)患有PTLD(7例女性,22例男性),占移植后所有恶性肿瘤的72.5%。22例(75.8%)发展为非霍奇金淋巴瘤,7例患者(24.2%)患有骨髓瘤。21例患者(72.4%)通过受累器官活检确诊,5例患者(17.2%)通过细针穿刺细胞学确诊。3例患者仅在尸检时确诊。PTLD确诊时的平均年龄为41.9岁(范围21 - 69岁)。从移植到PTLD诊断的时间间隔为3个月至144个月,中位数为48个月。仅5例患者(17.2%)在移植后1年内发生PTLD。12例患者在移植后1 - 5年发生PTLD,12例患者在移植后5 - 10年发生PTLD。18例患者(82%)的器官受累为结外受累。13例(59%)患者有播散性疾病,9例(41%)患者有单个器官的局限性受累(脑 - 3例,肝 - 1例,移植肾 - 1例,移植肾周围淋巴结 - 1例,腹膜后淋巴结 - 3例)。2例患者出现移植肾浸润。骨髓瘤患者表现为背痛、病理性骨折、不明原因贫血或移植肾功能障碍。20例PTLD起源于B细胞(70%)。对10例近期病例进行了CD20染色,其中8例呈阳性。在26例生前确诊的患者中,20例(69%)尽管接受了治疗,但在确诊后1年内死亡。总之,在我们的大多数患者中,PTLD在肾移植后较晚出现,且预后不良。大多数患者发病较晚表明其不太可能与爱泼斯坦 - 巴尔病毒相关。